Wouter Verhoeven, Dualyx CEO

Bel­gian biotech Du­a­lyx en­ters Treg field with $44M for 2024 clin­i­cal en­try

A young Bel­gian biotech aims to en­ter the clin­ic next year with a new Treg for au­toim­mune dis­eases, and now has $44 mil­lion in fi­nanc­ing to do so.

The Se­ries A will help Du­a­lyx take its first Treg can­di­date, DT-001, in­to a Phase I study in the sec­ond half of 2024, CEO Wouter Ver­ho­even told End­points News on Mon­day. Their first pro­gram is an an­ti­body go­ing af­ter TNF re­cep­tor 2, an im­muno­sup­pres­sive and “key im­mune mod­u­la­tor,” Ver­ho­even said, and they’ve yet to choose which au­toim­mune in­di­ca­tions it will go af­ter first.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.